相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glycogen kinase 3 inhibitor nanoformulation as an alternative strategy to inhibit PD-1 immune checkpoint
Parisa Badiee et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2022)
IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment
Qilin Li et al.
BIOMATERIALS (2021)
Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy
Ziling Zeng et al.
ADVANCED MATERIALS (2021)
A novel mouse model for checkpoint inhibitor-induced adverse events
Kieran Adam et al.
PLOS ONE (2021)
STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer
Jiaqi Shi et al.
CELLULAR IMMUNOLOGY (2021)
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Muyue Yang et al.
BIOACTIVE MATERIALS (2021)
Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8+ T-Cell-Dependent Tumor Activity
Tsubasa Watanabe et al.
CLINICAL CANCER RESEARCH (2020)
Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy
Yijia Liu et al.
BIOMATERIALS (2020)
Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase
Xuexiang Han et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors
Kuo-Ching Mei et al.
ACS NANO (2020)
Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects
Xue Jiang et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2020)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel
Jian Xu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors
Xiaomin Qian et al.
THERANOSTICS (2019)
Microfluidics for producing poly (lactic-co-glycolic acid)-based Check for pharmaceutical nanoparticles
Xuanyu Li et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade
Shuangjiang Yu et al.
ADVANCED MATERIALS (2018)
Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer
Qian Ye et al.
HUMAN PATHOLOGY (2018)
Molecular Insight into Drug-Loading Capacity of PEG-PLGA Nanoparticles for Itraconazole
Natalia Wilkosz et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2018)
Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy
Keman Cheng et al.
NANO LETTERS (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
Bing Feng et al.
ADVANCED MATERIALS (2018)
被撤回的出版物: Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway (Retracted article. See vol. 15, pg. 10735, 2021)
Jianqin Lu et al.
ACS NANO (2018)
PLGA-Based Nanoparticles in Cancer Treatment
Sima Rezvantalab et al.
FRONTIERS IN PHARMACOLOGY (2018)
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
Xiangjing Meng et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system
Young Ho Song et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Susan Ashton et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Yichao Chen et al.
NATURE COMMUNICATIONS (2016)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Fatemeh Sadat Tabatabaei Mirakabad et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Formation of Stable Nanocarriers by in Situ Ion Pairing during Block-Copolymer-Directed Rapid Precipitation
Nathalie M. Pinkerton et al.
MOLECULAR PHARMACEUTICS (2013)
PLGA-based nanoparticles: An overview of biomedical applications
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2012)
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-A review
Susanne Fredenberg et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
Jonathan R. Brody et al.
CELL CYCLE (2009)
Duplication of the genome in normal and cancer cell cycles
JL Bandura et al.
CANCER BIOLOGY & THERAPY (2002)
分享论文
